- call +1-201-465-4211
- email sales@marketquest.biz
- Call +1-201-465-4211
- Email: sales@marketquest.biz
The B-Cell Maturation Antigen (BCMA) Targeted Therapies market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global B-Cell Maturation Antigen (BCMA) Targeted Therapies market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Liver Cancer accounting for % of the B-Cell Maturation Antigen (BCMA) Targeted Therapies global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Bispecific Antibodies segment is altered to a % CAGR between 2022 and 2028.
Global key companies of B-Cell Maturation Antigen (BCMA) Targeted Therapies include Transposagen Biopharmaceuticals, Sutro Biopharma, Malin Corporation, Eureka Therapeutics, and firstVentury Equity, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
B-Cell Maturation Antigen (BCMA) Targeted Therapies market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Bispecific Antibodies
Antibody Drug Conjugates
Chimeric Antigen Receptor T-Cells
Market segment by Application, can be divided into
Liver Cancer
Respiratory Cancer
Brain Cancer
Others
Market segment by players, this report covers
Transposagen Biopharmaceuticals
Sutro Biopharma
Malin Corporation
Eureka Therapeutics
firstVentury Equity
Five Prime Therapeutics
Credit Suisse Securities
Dana-Farber Cancer Institute
Deerfield Partners
Onyx Pharmaceuticals
Juno Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe B-Cell Maturation Antigen (BCMA) Targeted Therapies product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of B-Cell Maturation Antigen (BCMA) Targeted Therapies, with revenue, gross margin and global market share of B-Cell Maturation Antigen (BCMA) Targeted Therapies from 2019 to 2022.
Chapter 3, the B-Cell Maturation Antigen (BCMA) Targeted Therapies competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and B-Cell Maturation Antigen (BCMA) Targeted Therapies market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe B-Cell Maturation Antigen (BCMA) Targeted Therapies research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Product Overview and Scope of B-Cell Maturation Antigen (BCMA) Targeted Therapies
1.2 Classification of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Type
1.2.1 Overview: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type in 2021
1.2.3 Bispecific Antibodies
1.2.4 Antibody Drug Conjugates
1.2.5 Chimeric Antigen Receptor T-Cells
1.3 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market by Application
1.3.1 Overview: Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Liver Cancer
1.3.3 Respiratory Cancer
1.3.4 Brain Cancer
1.3.5 Others
1.4 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size & Forecast
1.5 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast by Region
1.5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region, (2017-2022)
1.5.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2017-2028)
1.5.4 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2017-2028)
1.5.6 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
1.6.2 B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
1.6.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Trends Analysis
2 Company Profiles
2.1 Transposagen Biopharmaceuticals
2.1.1 Transposagen Biopharmaceuticals Details
2.1.2 Transposagen Biopharmaceuticals Major Business
2.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.1.4 Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Transposagen Biopharmaceuticals Recent Developments and Future Plans
2.2 Sutro Biopharma
2.2.1 Sutro Biopharma Details
2.2.2 Sutro Biopharma Major Business
2.2.3 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.2.4 Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Sutro Biopharma Recent Developments and Future Plans
2.3 Malin Corporation
2.3.1 Malin Corporation Details
2.3.2 Malin Corporation Major Business
2.3.3 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.3.4 Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Malin Corporation Recent Developments and Future Plans
2.4 Eureka Therapeutics
2.4.1 Eureka Therapeutics Details
2.4.2 Eureka Therapeutics Major Business
2.4.3 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.4.4 Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Eureka Therapeutics Recent Developments and Future Plans
2.5 firstVentury Equity
2.5.1 firstVentury Equity Details
2.5.2 firstVentury Equity Major Business
2.5.3 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.5.4 firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 firstVentury Equity Recent Developments and Future Plans
2.6 Five Prime Therapeutics
2.6.1 Five Prime Therapeutics Details
2.6.2 Five Prime Therapeutics Major Business
2.6.3 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.6.4 Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Five Prime Therapeutics Recent Developments and Future Plans
2.7 Credit Suisse Securities
2.7.1 Credit Suisse Securities Details
2.7.2 Credit Suisse Securities Major Business
2.7.3 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.7.4 Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Credit Suisse Securities Recent Developments and Future Plans
2.8 Dana-Farber Cancer Institute
2.8.1 Dana-Farber Cancer Institute Details
2.8.2 Dana-Farber Cancer Institute Major Business
2.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.8.4 Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Dana-Farber Cancer Institute Recent Developments and Future Plans
2.9 Deerfield Partners
2.9.1 Deerfield Partners Details
2.9.2 Deerfield Partners Major Business
2.9.3 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.9.4 Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Deerfield Partners Recent Developments and Future Plans
2.10 Onyx Pharmaceuticals
2.10.1 Onyx Pharmaceuticals Details
2.10.2 Onyx Pharmaceuticals Major Business
2.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.10.4 Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Onyx Pharmaceuticals Recent Developments and Future Plans
2.11 Juno Therapeutics
2.11.1 Juno Therapeutics Details
2.11.2 Juno Therapeutics Major Business
2.11.3 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
2.11.4 Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Juno Therapeutics Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Market Share in 2021
3.2.2 Top 10 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Head Office, Products and Services Provided
3.4 B-Cell Maturation Antigen (BCMA) Targeted Therapies Mergers & Acquisitions
3.5 B-Cell Maturation Antigen (BCMA) Targeted Therapies New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Market Share by Type (2017-2022)
4.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application (2017-2022)
5.2 Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2028)
6.2 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2028)
6.3 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
6.3.1 North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2028)
6.3.2 United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
6.3.3 Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
6.3.4 Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2028)
7.2 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2028)
7.3 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
7.3.1 Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2028)
7.3.2 Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
7.3.3 France B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
7.3.4 United Kingdom B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
7.3.5 Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
7.3.6 Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2028)
8.2 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2028)
8.3 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Region
8.3.1 Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Region (2017-2028)
8.3.2 China B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
8.3.3 Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
8.3.4 South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
8.3.5 India B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
8.3.7 Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2028)
9.2 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2028)
9.3 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
9.3.1 South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2028)
9.3.2 Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
9.3.3 Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2028)
10.2 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2028)
10.3 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size by Country
10.3.1 Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2028)
10.3.2 Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
10.3.4 UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) by Region (2017-2022)
Table 5. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Region (2023-2028)
Table 6. Transposagen Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Transposagen Biopharmaceuticals Major Business
Table 8. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 9. Transposagen Biopharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Sutro Biopharma Corporate Information, Head Office, and Major Competitors
Table 11. Sutro Biopharma Major Business
Table 12. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 13. Sutro Biopharma B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Malin Corporation Corporate Information, Head Office, and Major Competitors
Table 15. Malin Corporation Major Business
Table 16. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 17. Malin Corporation B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Eureka Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Eureka Therapeutics Major Business
Table 20. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 21. Eureka Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. firstVentury Equity Corporate Information, Head Office, and Major Competitors
Table 23. firstVentury Equity Major Business
Table 24. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 25. firstVentury Equity B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Five Prime Therapeutics Corporate Information, Head Office, and Major Competitors
Table 27. Five Prime Therapeutics Major Business
Table 28. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 29. Five Prime Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Credit Suisse Securities Corporate Information, Head Office, and Major Competitors
Table 31. Credit Suisse Securities Major Business
Table 32. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 33. Credit Suisse Securities B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Dana-Farber Cancer Institute Corporate Information, Head Office, and Major Competitors
Table 35. Dana-Farber Cancer Institute Major Business
Table 36. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 37. Dana-Farber Cancer Institute B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Deerfield Partners Corporate Information, Head Office, and Major Competitors
Table 39. Deerfield Partners Major Business
Table 40. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 41. Deerfield Partners B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Onyx Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 43. Onyx Pharmaceuticals Major Business
Table 44. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 45. Onyx Pharmaceuticals B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Juno Therapeutics Corporate Information, Head Office, and Major Competitors
Table 47. Juno Therapeutics Major Business
Table 48. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Product and Solutions
Table 49. Juno Therapeutics B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 51. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 52. Breakdown of B-Cell Maturation Antigen (BCMA) Targeted Therapies by Company Type (Tier 1, Tier 2 and Tier 3)
Table 53. B-Cell Maturation Antigen (BCMA) Targeted Therapies Players Head Office, Products and Services Provided
Table 54. B-Cell Maturation Antigen (BCMA) Targeted Therapies Mergers & Acquisitions in the Past Five Years
Table 55. B-Cell Maturation Antigen (BCMA) Targeted Therapies New Entrants and Expansion Plans
Table 56. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) by Type (2017-2022)
Table 57. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Type (2017-2022)
Table 58. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Forecast by Type (2023-2028)
Table 59. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2022)
Table 60. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Forecast by Application (2023-2028)
Table 61. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2022) & (USD Million)
Table 62. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2023-2028) & (USD Million)
Table 63. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2022) & (USD Million)
Table 64. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2023-2028) & (USD Million)
Table 65. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2022) & (USD Million)
Table 66. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2023-2028) & (USD Million)
Table 67. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2022) & (USD Million)
Table 68. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2023-2028) & (USD Million)
Table 69. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2022) & (USD Million)
Table 70. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2023-2028) & (USD Million)
Table 71. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2022) & (USD Million)
Table 72. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2023-2028) & (USD Million)
Table 73. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2022) & (USD Million)
Table 74. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2023-2028) & (USD Million)
Table 75. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2022) & (USD Million)
Table 76. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2023-2028) & (USD Million)
Table 77. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Region (2017-2022) & (USD Million)
Table 78. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Region (2023-2028) & (USD Million)
Table 79. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2022) & (USD Million)
Table 80. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2023-2028) & (USD Million)
Table 81. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2022) & (USD Million)
Table 82. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2023-2028) & (USD Million)
Table 83. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2022) & (USD Million)
Table 84. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2023-2028) & (USD Million)
Table 85. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2017-2022) & (USD Million)
Table 86. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Type (2023-2028) & (USD Million)
Table 87. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2017-2022) & (USD Million)
Table 88. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Application (2023-2028) & (USD Million)
Table 89. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2017-2022) & (USD Million)
Table 90. Middle East & Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Picture
Figure 2. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Type in 2021
Figure 3. Bispecific Antibodies
Figure 4. Antibody Drug Conjugates
Figure 5. Chimeric Antigen Receptor T-Cells
Figure 6. B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Application in 2021
Figure 7. Liver Cancer Picture
Figure 8. Respiratory Cancer Picture
Figure 9. Brain Cancer Picture
Figure 10. Others Picture
Figure 11. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Region (2017-2028)
Figure 14. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Region in 2021
Figure 15. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Drivers
Figure 21. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Restraints
Figure 22. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Trends
Figure 23. Transposagen Biopharmaceuticals Recent Developments and Future Plans
Figure 24. Sutro Biopharma Recent Developments and Future Plans
Figure 25. Malin Corporation Recent Developments and Future Plans
Figure 26. Eureka Therapeutics Recent Developments and Future Plans
Figure 27. firstVentury Equity Recent Developments and Future Plans
Figure 28. Five Prime Therapeutics Recent Developments and Future Plans
Figure 29. Credit Suisse Securities Recent Developments and Future Plans
Figure 30. Dana-Farber Cancer Institute Recent Developments and Future Plans
Figure 31. Deerfield Partners Recent Developments and Future Plans
Figure 32. Onyx Pharmaceuticals Recent Developments and Future Plans
Figure 33. Juno Therapeutics Recent Developments and Future Plans
Figure 34. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Players in 2021
Figure 35. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 36. Global Top 3 Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share in 2021
Figure 37. Global Top 10 Players B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share in 2021
Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 39. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Type in 2021
Figure 40. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share Forecast by Type (2023-2028)
Figure 41. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Share by Application in 2021
Figure 42. Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Share Forecast by Application (2023-2028)
Figure 43. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Type (2017-2028)
Figure 44. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Application (2017-2028)
Figure 45. North America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Country (2017-2028)
Figure 46. United States B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. Canada B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Mexico B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Type (2017-2028)
Figure 50. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Application (2017-2028)
Figure 51. Europe B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Country (2017-2028)
Figure 52. Germany B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. France B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. United Kingdom B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Russia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Italy B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Type (2017-2028)
Figure 58. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Application (2017-2028)
Figure 59. Asia-Pacific B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Region (2017-2028)
Figure 60. China B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Japan B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. South Korea B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. India B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Southeast Asia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Australia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Type (2017-2028)
Figure 67. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Application (2017-2028)
Figure 68. South America B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Country (2017-2028)
Figure 69. Brazil B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Argentina B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Type (2017-2028)
Figure 72. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Sales Market Share by Application (2017-2028)
Figure 73. Middle East and Africa B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue Market Share by Country (2017-2028)
Figure 74. Turkey B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. UAE B-Cell Maturation Antigen (BCMA) Targeted Therapies Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Methodology
Figure 78. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
